Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Molecular Partners AGNASDAQ: MOLN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 37.5M shares rose 1.7% year over year, behind the +9.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.7% toward the trailing-twelve-month pace of +9.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
37.5M+0.2% QoQ
Last fiscal yearDec 2025
37.27M+9.5% YoY
LTMMar 2026
37.43M+9.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.7%——
1 year+9.5%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
37.27M CHF
Year-over-year change
+9.5%
4-year CAGR
+4.7%

Weighted Avg Shares vs competitors

How MOLN compares with its peers on the latest reported figures

  • MOLN's LTM Mar 2026 weighted avg shares of 37.43M shares is the 7th highest of the 9 companies compared; the peer median is 70.61M shares.
  • Its year-over-year change of +9.0% is the 7th highest of 9, against a peer median of +31.5%.
  • Over three fiscal years its annual growth of +4.7% compares with a peer median of +32.4%.
MOLN Competitors Peer median
Weighted Avg Shares for MOLN and competitors
Company Period LTM YoY 3-year CAGR
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding MOLN) 70.61M+31.5%+32.4%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.33M189.56M7.04M4.97M0
Cost of Revenue55.72M50.75M47.84M47.5M2.58M
Gross Profit(46.39M)138.81M(40.81M)(42.53M)(2.58M)
Gross Margin-497.2%73.2%-579.8%-855.8%—
Research & Development55.72M50.75M48.78M48.6M40.19M
Selling, General & Admin16.91M21.82M19M17.16M14.87M
Operating Expenses72.75M72.94M20.3M18.68M50.89M
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
EBITDA(60.66M)119M(59.52M)(51.65M)(59.49M)
EBITDA Margin-650.2%62.8%-845.6%-1039.2%—
Operating Income(63.42M)116.61M(61.11M)(61.22M)(58.12M)
Operating Margin-679.7%61.5%-868.3%-1231.7%—
Interest Income108.28K1.2M4.28M3.38M1.52M
Interest Expense608.14K648.12K49K25K18K
Other Income / Expenses(365K)1.24M(876K)7.18M(3.53M)
Income Before Tax(63.78M)117.85M(61.98M)(54.04M)(61.65M)
Pre-Tax Margin-683.6%62.2%-880.7%-1087.3%—
Income Tax Expense2K002K2K
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Net Margin-683.7%62.2%-880.7%-1087.4%—
EPS (Basic)(2.06)3.63(1.89)(1.59)(1.65)
EPS (Diluted)(2.06)3.54(1.89)(1.59)(1.65)
Weighted Avg Shares31.01M32.47M32.77M34.03M37.27M
Weighted Avg Shares (Diluted)31.01M33.27M32.77M34.03M37.27M

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.